BIOTECanada responds to CADTH's proposal on Time-Limited Recommendations

BIOTECanada welcomed the opportunity to comment on CADTH’s proposal to create a Time-Limited Recommendation pathway for select therapeutic products. This is an incremental first step towards health technology assessment processes in Canada that are agile, responsive, and consider the evolution of evidence through a medicine’s lifecycle, by addressing uncertainty that may exist at the time of a medicine’s launch, and enabling early patient access to therapies with promising value.